Lung Transplantation and Lung Diseases: Molecular Pathogenesis and Advanced Therapies

Dear Colleagues,

Lung transplantation is an increasingly therapeutical option for patients with severe end-stage pulmonary disease in a highly selective population. While transplantation is the definitive therapy, the success rates are reflected in the improved long-term survival of patients within the last few decades.

This Special Issue comprehensively delves into the intricate realm of lung diseases and lung transplantations. From understanding the origins of pathogenesis to the latest advancements in therapeutic approaches, our special edition provides a holistic view of the field.

Our focuses are as follows:

1. Molecular Insights: Explore the latest discoveries in molecular pathogenesis and pathways associated with lung diseases, shedding light on potential targets for intervention.
2. Transplantation Advances: Delve into the world of lung transplantation, examining the evolving landscape of techniques and innovations that enhance transplant success rates.
   - Pre-transplant management (e.g., introduction of the lung allocation scores/LAS);
   - Surgical techniques (ECMO concept/ lung perfusion);
   - Post-transplant management (early diagnosis of rejection, new immunosuppression concepts).
3. Therapeutic Strategies: Gain insights into advanced therapies, including gene therapies, stell cell therapies, immunotherapies, and personalized medicine, revolutionizing the treatment landscape for lung diseases.

This Special Issue caters to a diverse audience, including researchers, healthcare professionals, and students interested in gaining a comprehensive understanding of lung diseases and transplantation. Controlling the management of all phases of lung transplantation contributes to a better quality of life and improved long-term survival for patients with underlying end-stage diseases.

Notes: Data on molecular mechanisms or pathophysiology are essential, and papers that only contain clinical trials/data are not acceptable.

Dr. Christopher Lambers
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• lung disease
• lung transplantation
• ECMO
• EVLP
• LAS
• antibody-mediated rejection (AMR)
• CLAD
• RAS/BOS
• immunosuppression
• pathogenesis
• cell-free DNA
• IPF therapies
• gene therapies
• stem cell therapies
• immunotherapies